Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide.
Nat Med
; 10(10): 1128-32, 2004 Oct.
Article
em En
| MEDLINE
| ID: mdl-15448687
ABSTRACT
The JNK pathway is known to be activated in several tissues in the diabetic state, and is possibly involved in the development of insulin resistance and suppression of insulin biosynthesis. Here we show a potential new therapy for diabetes using cell-permeable JNK-inhibitory peptide. Intraperitoneal administration of the peptide led to its transduction into various tissues in vivo, and this treatment markedly improved insulin resistance and ameliorated glucose tolerance in diabetic mice. These data indicate that the JNK pathway is critically involved in diabetes and that the cell-permeable JNK-inhibitory peptide may have promise as a new therapeutic agent for diabetes.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Peptídeos
/
Terapia Genética
/
Proteína Quinase 8 Ativada por Mitógeno
/
Diabetes Mellitus Tipo 2
Limite:
Animals
Idioma:
En
Revista:
Nat Med
Assunto da revista:
BIOLOGIA MOLECULAR
/
MEDICINA
Ano de publicação:
2004
Tipo de documento:
Article
País de afiliação:
Japão